Relationship of serum beta‐synuclein with blood biomarkers and brain atrophy. Issue 4 (21st September 2022)

• Record Type: Journal Article
• Authors: Oeckl, Patrick; Anderl‐Straub, Sarah; Danek, Adrian; Diehl‐Schmid, Janine; Fassbender, Klaus; Fliessbach, Klaus; Halbgebauer, Steffen; Huppertz, Hans‐Jürgen; Jahn, Holger; Kassubek, Jan; Kornhuber, Johannes; Landwehrmeyer, Bernhard; Lauer, Martin; Prudlo, Johannes; Schneider, Anja; Schroeter, Matthias L.; Steinacker, Petra; Volk, Alexander E.; Wagner, Matias; Winkelmann, Juliane; Wiltfang, Jens; Ludolph, Albert C.; Otto, Markus
• Is Part Of: Alzheimer's & dementia. Volume 19:Issue 4(2023)
• Page Start: 1358
• Page End: 1371
• Publication Date: 2022-09-21
• Subjects: Alzheimer's disease -- beta‐synuclein -- blood biomarker -- brain atrophy -- dementia -- frontotemporal lobar degeneration -- FTLD -- NfL -- p‐tau181 -- synaptic degeneration; Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1002/alz.12790
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Background: Recent data support beta‐synuclein as a blood biomarker to study synaptic degeneration in Alzheimer's disease (AD). Methods: We provide a detailed comparison of serum beta‐synuclein immunoprecipitation – mass spectrometry (IP‐MS) with the established blood markers phosphorylated tau 181 (p‐tau181) (Simoa) and neurofilament light (NfL) (Ella) in the German FTLD consortium cohort ( n = 374) and its relation to brain atrophy (magnetic resonance imaging) and cognitive scores. Results: Serum beta‐synuclein was increased in AD but not in frontotemporal lobar degeneration (FTLD) syndromes. Beta‐synuclein correlated with atrophy in temporal brain structures and was associated with cognitive impairment. Serum p‐tau181 showed the most specific changes in AD but the lowest correlation with structural alterations. NfL was elevated in all diseases and correlated with frontal and temporal brain atrophy. Discussion: Serum beta‐synuclein changes differ from those of NfL and p‐tau181 and are strongly related to AD, most likely reflecting temporal synaptic degeneration. Beta‐synuclein can complement the existing panel of blood markers, thereby providing information on synaptic alterations. Highlights: Blood beta‐synuclein is increased in Alzheimer's disease (AD) but not in frontotemporal lobar degeneration (FTLD) syndromes. Blood beta‐synuclein correlates with temporal brain atrophy in AD. Blood beta‐synuclein correlates with cognitive impairment in AD. The pattern of blood beta‐synuclein changes in the investigated diseases is different to phosphorylated tau 181 (p‐tau181) and neurofilament light (NfL).